PRESS RELEASE published on 04/29/2024 at 18:00, 4 months 19 days ago THERANEXUS PUBLIE SES RESULTATS ANNUELS 2023 ET FAIT LE POINT SUR SES ACTIVITÉS Theranexus, société biopharmaceutique à lyon, publie ses résultats annuels 2023, sa trésorerie 31 mars 2024 et ses activités. Nouvelle Directrice administrative et financière. Projets innovants dans maladies neurologiques rares Résultats Annuels Trésorerie Theranexus Maladies Neurologiques Rares Christine Placet
BRIEF published on 04/26/2024 at 18:05, 4 months 22 days ago Theranexus publie ses informations sur les droits de vote et le capital pour mars 2024 Droits De Vote Capital Social Biopharmaceutique Theranexus Neurologie
BRIEF published on 04/26/2024 at 18:05, 4 months 22 days ago Theranexus releases voting rights and capital information for March 2024 Share Capital Voting Rights Biopharmaceutical Neurology Theranexus
PRESS RELEASE published on 04/26/2024 at 18:00, 4 months 22 days ago Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital Theranexus publie le nombre d'actions et de droits de vote au 31 mars 2024, renforçant sa transparence. Détails sur son engagement dans le traitement des maladies neurologiques rares Droits De Vote Capital Social Biopharmaceutique Theranexus Maladies Neurologiques Rares
BRIEF published on 04/23/2024 at 07:35, 4 months 26 days ago Theranexus, Diverchim and INSERM obtain funding of 4.7 million euros for the development of a new antisense oligonucleotide Biothérapies France 2030 Funding Antisense Oligonucleotide Rare Neurological Diseases Autophagy
BRIEF published on 04/23/2024 at 07:35, 4 months 26 days ago Theranexus, Diverchim et l'INSERM obtiennent un financement de 4.7 millions d'euros pour le développement d'un nouvel oligonucléotide antisens Financement France 2030 Oligonucléotide Antisens Maladies Rares Neurologiques Autophagie Biothérapies
PRESS RELEASE published on 04/23/2024 at 07:30, 4 months 26 days ago Theranexus, Diverchim and Inserm awarded EUR 4.7 million in funding under the "Innovations in biotherapies and biomanufacturing" call for proposals from France 2030 to develop a novel antisense oligonucleotide Theranexus, Diverchim, and Inserm's ARNA laboratory receive €4.7 million funding from French Government to develop autophagy activation therapy for rare neurological diseases under the PickASO project in collaboration with France 2030 Theranexus Diverchim Autophagy Activation Therapy Inserm PickASO Project
PRESS RELEASE published on 04/23/2024 at 07:30, 4 months 26 days ago Theranexus, Diverchim et l'INSERM bénéficient d'un financement de 4.7 millions d'euros dans le cadre de l'appel à projets " Innovations en Biothérapies et Bioproduction " de France 2030, pour développer un nouvel oligonucléotide antisens Theranexus, Diverchim, and ARNA laboratory of INSERM receive 4.7 million euros from the French government to develop a groundbreaking autophagy activation therapy called PickASO Theranexus Diverchim ARNA Laboratory Autophagy Activation Therapy PickASO
BRIEF published on 04/18/2024 at 18:05, 5 months ago Theranexus and BBDF Announce Positive Results for Batten-1 Phase 1/2 Study Clinical Study Rare Diseases Theranexus Batten-1 Batten Disease CLN3
BRIEF published on 04/18/2024 at 18:05, 5 months ago Theranexus et BBDF annoncent des résultats positifs pour l'étude de phase 1/2 de Batten-1 Étude Clinique Maladies Rares Theranexus Maladie De Batten CLN3 Batten-1
Published on 09/19/2024 at 17:30, 29 minutes ago Airborne Geophysical Survey Completed at Pine Channel Gold Project, Saskatchewan
Published on 09/19/2024 at 17:00, 59 minutes ago Cypress Creek Consulting Advises Charter Communications on Inaugural Securitization Financing Facility
Published on 09/19/2024 at 15:45, 2 hours 14 minutes ago eLearners Make eLearning a Daily or Weekly Habit, Voices' eLearning Report Finds
Published on 09/19/2024 at 15:20, 2 hours 39 minutes ago Taurus secures "Best Digital Assets Solution" at 2024 Global BankTech Awards
Published on 09/19/2024 at 15:01, 2 hours 58 minutes ago ful. CashPay: Revolutionizing Healthcare Access for Employers With Uninsured Team Members
Published on 09/19/2024 at 17:45, 13 minutes ago AFG Holding SA acquiert une participation majoritaire dans le groupe allemand Access Holding et prend ainsi le contrôle de
Published on 09/19/2024 at 17:09, 49 minutes ago Adler Group S.A. announces the completion of the comprehensive recapitalisation
Published on 09/19/2024 at 17:00, 58 minutes ago EQS-Adhoc: SMT Scharf AG: Yankuang new strategic core shareholder
Published on 09/19/2024 at 15:10, 2 hours 48 minutes ago Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc
Published on 09/19/2024 at 15:08, 2 hours 51 minutes ago Form 8.3 - The Vanguard Group, Inc.: Ascential plc
Published on 09/19/2024 at 17:45, 14 minutes ago Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Published on 09/19/2024 at 17:45, 14 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Published on 09/19/2024 at 17:45, 14 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)